Compare Ginkgo Bioworks Holdings Inc (DNA) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs EPR Properties — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.07 (market cap $590.53M), while EPR Properties trades at $60.37 (market cap $4.56B). The key difference: EPR Properties is far larger — about 7.7× Ginkgo Bioworks Holdings Inc's market cap, and EPR Properties pays a 6.25% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | EPR | |
|---|---|---|
Market Cap | $590.53M | $4.56B |
Sector | Health | Real Estate |
52-Week High | $16.14 | $60.81 |
52-Week Low | $5.48 | $48.71 |
Enterprise Value | $627.78M | $7.62B |
Dividend Yield | — | 6.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
EPR Properties trades at $59.81, up 0.32% today, with a bullish technical signal from moving averages and strong fundamentals including a 39.93% net income margin and consistent dividend payments. Recent earnings show mixed results with a Q1 2026 miss but previous quarters beating expectations. The company maintains robust cash flow from operations of $421 million in 2025 and high portfolio occupancy.
Outlook remains positive with a consensus price target of $63.00, though risks include reliance on experiential real estate and market sensitivity. The stock offers a compelling blend of income and growth, supported by analyst buy ratings and recent acquisitions like the Six Flags park deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
